Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. GELS
stocks logo

GELS

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Valuation Metrics

The current forward P/E ratio for Gelteq Ltd (GELS.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Gelteq Ltd 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

GELS News & Events

Events Timeline

(ET)
2025-12-09
09:20:00
Gelteq Enters Three-Year Sales Agreement with Shenzhen Mana, Expected Revenue of $1.3 Million
select
2025-12-05 (ET)
2025-12-05
10:50:00
Gelteq Announces Preclinical Findings Demonstrating Effectiveness of Gel Platform
select
2025-11-24 (ET)
2025-11-24
08:43:18
Gelteq Reports Encouraging Preclinical Findings for Its Gel Formula
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.5
12-09Globenewswire
Gelteq Enters 3-Year Sales Agreement with Mana, Projecting $1.3M Revenue
  • Market Expansion Opportunity: Gelteq has signed a three-year sales agreement with Shenzhen Mana Health Management Co. Ltd., projecting a minimum revenue of approximately $1.3 million during the term, thereby accelerating its entry into China's rapidly growing nutritional product market.
  • Leveraging Channel Advantages: Mana's strong digital presence and offline retail channels will effectively promote Gelteq's sugar-lowering nutritional formulations, utilizing its existing platform to reach a broader consumer base across the country.
  • Product Portfolio Enrichment: The agreement not only covers sugar-lowering products but also paves the way for introducing additional nutritional products incorporating Gelteq's proprietary technology, further enhancing the company's product diversity.
  • Deepening Strategic Partnerships: Gelteq CEO Nathan Givoni stated that this collaboration represents a significant milestone in the Chinese market, aiming to generate predictable revenue through long-term commitments with distributors, thereby strengthening its strategic position in the global nutritional products market.
[object Object]
Preview
3.5
12-06Globenewswire
Gelteq's Novel Oral Delivery System Significantly Enhances Bioavailability
  • Bioavailability Enhancement: Gelteq's studies demonstrate that its proprietary gel platform increases the bioavailability of oil-soluble compounds by 300% within the first hour, which is critical for rapid onset of action and could transform drug development paradigms.
  • Improved Absorption Efficiency: Over 24 hours, the gel matrix enhances overall absorption by more than 20%, addressing poor solubility issues while potentially reducing development costs and increasing market competitiveness.
  • Safety and Compatibility: The research indicates that the gel effectively controls the movement of drugs through the digestive system, ensuring full clearance of active pharmaceutical ingredients, thereby enhancing its safety and compatibility as an oral delivery system.
  • Significant Market Potential: With over 40% of approved drugs and up to 90% of developmental candidates facing solubility issues, Gelteq's technology offers a promising solution for pharmaceutical companies, likely attracting substantial investment to tackle this industry challenge.
[object Object]
Preview
3.5
11-24Newsfilter
Gelteq Reports 38-45% Bioavailability Increase in New Antihistamine Gel Formulation
  • Bioavailability Improvement: Gelteq's new gel formulation shows a 38-45% increase in bioavailability compared to a leading antihistamine in preclinical studies. This significant enhancement indicates the technology's potential to improve oral drug absorption, positively impacting patient compliance.
  • Technical Milestone: CEO Nathan Givoni stated that these results represent a major technical and commercial milestone for the company, validating its platform's ability to enhance the performance of established drugs. This advancement lays the groundwork for Gelteq to pursue a broader portfolio of pharmaceutical opportunities.
  • Broad Application Potential: The water-soluble nature of the test compound supports the platform's application across other water-soluble drug classes, significantly broadening the company's commercial scope. This expansion could encompass a wider range of therapeutically relevant compounds.
  • FDA Approval Plans: Gelteq anticipates using these results to further pursue an FDA approval pathway for an antihistamine product and to increase engagement with potential pharmaceutical partners. This strategy aims to create immediate value in next-generation drug delivery formats.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Gelteq Ltd (GELS) stock price today?

The current price of GELS is 1.01 USD — it has decreased -7.34 % in the last trading day.

arrow icon

What is Gelteq Ltd (GELS)'s business?

Gelteq Limited is an Australia-based clinical and science-based company. The Company is focused on developing and commercializing white-label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products. The Company offers a complete end-to-end service for the development of new products and the conversion of existing products and formulations into gels. Its product suite consists of multiple products that sit within five core verticals - for pets, sports, pharmaceuticals (pharma), over-the-counter (OTC) and nutraceuticals. The Company’s delivery system provides pharma and nutraceutical enhancements throughout every stage of ingestion in both animals and humans, addressing the complete experience from the point of ingestion to final absorption. The Company also offers a versatile portfolio of pre-tested and market-ready proprietary formulations that can be white-labelled.

arrow icon

What is the price predicton of GELS Stock?

Wall Street analysts forecast GELS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GELS is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Gelteq Ltd (GELS)'s revenue for the last quarter?

Gelteq Ltd revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Gelteq Ltd (GELS)'s earnings per share (EPS) for the last quarter?

Gelteq Ltd. EPS for the last quarter amounts to -0.12 USD, increased 20.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Gelteq Ltd (GELS)'s fundamentals?

The market is revising No Change the revenue expectations for GELS for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -36.88%.
arrow icon

How many employees does Gelteq Ltd (GELS). have?

Gelteq Ltd (GELS) has 7 emplpoyees as of December 13 2025.

arrow icon

What is Gelteq Ltd (GELS) market cap?

Today GELS has the market capitalization of 11.68M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free